๋ฅํ๋ก๋ผ์ด๋
**๋ฅํ๋ก๋ผ์ด๋(Leuprolide)**๋ ์ฑ์ ์๊ทนํธ๋ฅด๋ชฌ ๋ฐฉ์ถํธ๋ฅด๋ชฌ(GnRH)์ ํฉ์ฑ 9ํฉํ์ด๋ ์ ์ฌ์ฒด์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก **ํ๋ฟ์ ๋ถ์ ๊ด๋ จ ๋ด๋ถ๋น๋ณ์ฆ**์ ๋ด๊ณผ์ ์น๋ฃ์ **์ฌ์ก ์กฐ๋ฅ์ ๋ถ์ ์ ํ ์ฐ๋ ๋๋ ๋ฒ์ ์ฅ์ **๋ฅผ ์ต์ ํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * **ํ๋ฟ ๋ถ์ ์งํ**: ๊ฐ์ ๋ฌ๋ฆฌ ํ๋ฟ์ ๋ถ์ ์งํ์ ์ฝ๋ฅดํฐ์์ด ์๋ ๊ณผ๋ํ ์ฑํธ๋ฅด๋ชฌ(์๋๋ก๊ฒ/์์คํธ๋ก๊ฒ)์ ์ํด ๋ฐ์ํฉ๋๋ค. ๋ฅํ๋ก๋ผ์ด๋๋ ์ด๋ฌํ ์์ ์ฆ์(์: ํ๋ชจ, ์ธ์๋ถ ๋ถ์ข , ์์์ฆ)์ ์ ๋ฐํ๋ ํธ๋ฅด๋ชฌ ์ถ์ ํจ๊ณผ์ ์ผ๋ก ์ต์ ํฉ๋๋ค. * **์ ํ**: 1, 3 ๋๋ 4๊ฐ์ ๋์ ์ง์์ ์ผ๋ก ๋ฐฉ์ถ๋๋ ์ฅ๊ธฐ ์ง์ํ **๋ฐํฌ ์ฃผ์ฌ์ **(๋ฏธ๋ฆฝ๊ตฌ)๋ก ๊ฐ์ฅ ํํ๊ฒ ํฌ์ฌ๋ฉ๋๋ค. * **๋น์ฉ**: ์ด ์ฝ๋ฌผ์ ๋งค์ฐ ๋น์ธ์ง๋ง, ์กฐ์ ์ฝ๊ตญ์์ ํน์ ๋๋ฌผ์ ์ํด ์ธ์ฒด์ฉ ๋ฐ์ด์์ ๋ ์ ๋ ดํ ์๋์ผ๋ก ๋๋์ด ์ ๊ณตํ๋ ๊ฒฝ์ฐ๊ฐ ๋ง์ต๋๋ค. * **์์ ์ฑ**: ๊ธฐํ ์ ๋ฐ์ฑ์ด ๋งค์ฐ ๋์ผ๋ฉฐ ์์ ์ค์๋ ์ ๋ ๊ธ๊ธฐ์ ๋๋ค.
์์ฉ ๊ธฐ์ : Leuprolide acts as a **luteinizing hormone-releasing hormone (LHRH/GnRH) agonist**. * **Initial Phase (Flare)**: Upon initial administration, it stimulates the pituitary gland, causing a transient surge in **luteinizing hormone (LH)** and **follicle-stimulating hormone (FSH)**. * **Downregulation Phase**: Continuous exposure via depot formulation causes profound downregulation and desensitization of **GnRH receptors** in the anterior pituitary. * **Suppression**: This negative feedback โ halts the release of **LH** and **FSH** โ drastically decreases serum levels of gonadal steroids (**estrogen** and **androgens**), thereby resolving hormonally driven clinical signs.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Adrenal associated endocrinopathy (30-day formulation) ยท 100 micrograms/kg (females) or 200 micrograms/kg (males) ยท IM ยท q30d ยท Lifelong/Ongoing ยท Proven effective for management of the disease.
- Adrenal associated endocrinopathy (3-month formulation) ยท 1 mg (total dose) ยท IM ยท every 60-75 days ยท Lifelong/Ongoing ยท Length of control in intact ferrets in Spring; may be useful for annual Dec/Feb suppression.
- Adrenal associated endocrinopathy (4-month formulation) ยท 2 mg (total dose) ยท IM ยท every 70-80 days ยท Lifelong/Ongoing ยท Anecdotal time before signs reappear; may be useful for annual Dec/Feb suppression.
- Adrenal associated endocrinopathy (30-day formulation, weight-based) ยท <1 kg: 100 micrograms; >1 kg: 200 micrograms ยท IM ยท q30d ยท Lifelong/Ongoing ยท Generally diluted from original concentration to negate muscle necrosis. Diluted form appears active after freezing for a year (though manufacturer advises against freezing).
- Adrenal associated endocrinopathy (1-month depot form) ยท 100-250 micrograms/kg ยท IM ยท every 4 weeks until signs resolve, then every 4-8 weeks as needed ยท Lifelong ยท Larger ferrets may require the higher dosage range.
- Inappropriate egg laying in Cockatiels (if management changes fail) ยท 800 micrograms/kg IM every 2 weeks for 3 injections ยท IM ยท q14d ยท 3 injections ยท Often effective at reducing reproduction at least in the short-term.
- Inhibit egg laying in pet birds ยท 100 micrograms/kg per day. Multiply dose by number of days for effect and give once monthly (e.g., 100 mcg/kg x 28 days = 2800 mcg/kg dose) ยท IM ยท q30d ยท Monthly
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Pregnancy (FDA Category X - major fetal abnormalities may result)
- Nursing/lactating animals (use with extreme caution, excretion in milk is unknown)
์ด์๋ฐ์
- Pain or irritation at the injection site
- Dyspnea (reported in ferrets)
- Lethargy (reported in ferrets)
- Tachyphylaxis (higher dosages required over time to obtain the same effect in ferrets)
- Transient worsening of clinical signs (flare effect) shortly after initial administration
๋ชจ๋ํฐ๋ง
- Ferrets: Resolution of clinical signs (decreased vulvar swelling, reduced pruritus, cessation of undesirable sexual behaviors/aggression, and increased hair regrowth)
- Birds: Decreased egg-laying behavior and physical reproductive activity
- Injection site for signs of pain, irritation, or necrosis
๊ณผ์ฉ๋
Because of its high expense and the method of dosing (usually administered by the veterinarian in-clinic), an acute overdose is highly unlikely. Studies in laboratory animals at massive dosages of up to 5 grams/kg IM produced no untoward effects, suggesting a wide margin of safety for acute exposure.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.